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httcense.Abstract Purpose: To evaluate the short and long term efﬁciency of catheter directed thrombol-
ysis using recombinant tissue type plasminogin activator (r-TPA; Actilyse), in treating acute deep
venous thrombosis of the lower limb.
Material and methods: Twenty-eight patients with acute lower limb deep venous thrombosis under-
went treatment by direct intra clot injection of thrombolytic therapy; Actilyse.
Result: Thrombus lysis was completed in 23 (82.2%) of 28 patients, partial in 4 (14.3%) patients
and not achieved in one (3.5%) patient. There was no major complication. There was no rethrom-
bosis or post thrombotic syndrome in any of the treated 23 patients over the follow up period of one
year.
Conclusion: The treatment of acute lower limb deep venous thrombosis using recombinant tissue
type plasminogin activator (r-TPA; Actilyse), is safe, effective and achieves signiﬁcantly better short
and long term clinical outcome for patients.
 2012 Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
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Deep venous thrombosis of the lower extremity is recognized
as a cause of both pulmonary embolism and the post throm-
botic syndrome. The therapeutic goals for treating the patients
with acute DVT include, diminishing the severity and duration080608; fax: +20 226359982.
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p://dx.doi.org/10.1016/j.ejrnm.2012of lower extremity symptoms, preventing pulmonary embo-
lism, minimizing the risk of recurrent venous thrombosis and
preventing the post thrombotic syndrome [1,2]. Success in
the achievement of these clinical goals will minimize the mor-
bidity and mortality of pulmonary embolism and will diminish
the sequelae of post thrombotic syndrome [3]. Early thrombus
removal is a logical approach to improve the long term out-
come of DVT [4]. Although anticoagulation (heparin followed
by oral anticoagulation) is currently considered the standard
of care for protecting the patient from the manifestation of
post thrombotic syndrome which can appear months to years
after the acute episode of DVT [5,6]. However, this regimen
does not promote lysis to reduce the thrombus load and does
not restore the venous valve function [7]. Thrombolytic
therapy is attractive, because it can potentially help achieveProduction and hosting by Elsevier B.V. All rights reserved.
.10.001
Table 1 Symptoms and location of DVT in 28 patients.
Initial symptoms No. of
patients
Edema 25
Pain 28
Location and extension of the thrombus:
 Poplitofemoral thrombus extending to the iliac vein 22
 Poplitofemoral thrombus extending up to the IVC 6
58 M. Gomaa et al.restoration of the lumen and removal of the thrombus lining
the venous valves. Two goals may be achieved: relief of venous
outﬂow obstruction and preservation of valve function [8]. The
frequently used thrombolytic agents that rapidly clear venous
thrombosis include streptokinase, urokinase, and recombinant
tissue type plasminogin activator (r,TPA) like alteplase and
actilyse. It can be used systemically or loco regional [9]. Trans-
catheter regional infusion allows higher concentrations of the
thrombolytic agent to be introduced directly into the thrombus
[10]. However, continuous infusion potentially results in pro-
longed exposure of the systemic circulation to thrombolytic
agents which can increase the risk of bleeding [11]. The pur-
pose of this study was to determine the feasibility and safety
of catheter directed thrombolysis for treatment of lower
extremity DVT using recombinant human tissue type plasmi-
nogin activator; actilyse.
2. Patients and methods
Twenty-eight consecutive patients (15 women and 13 men, age
range of 17–76 years; mean age of 38 years) with recent lower
extremity venous thrombosis of less than 15 days but without
clinically relevant signs of pulmonary embolism, were included
in this prospective study. The onset of the thrombosis was
based upon the date of the initial clinical symptoms. The study
was conducted in Doctor Soliman Fakeeh Hospital, Jeddah,
KSA between April 2008 and August 2011. Patients were se-
lected on the basis of the following criteria: (a) symptomatic
lower extremity thrombus conﬁrmed by duplex ultrasound;
(b) severe clinical symptoms; pain and swelling, which prohibit
standing on the leg; and (c) no contraindication to infusion of
the thrombolytic agent. Contraindications to thrombolytic
agents included active internal bleeding; cerebrovascular acci-
dent within previous 2 months; recent major trauma or sur-
gery; recent gastrointestinal bleeding; severe hypertension;
pregnancy, lactation or delivery within the last 20 days; malig-
nant disease; acute pancreatitis; hepatic failure; renal failure
and coagulopathy. All patients gave written informed consent
to participate after the risks and beneﬁts of treatment were
fully explained.
The left leg was involved in 18 patients, the right leg in 9
patients and the last patient had bilateral thrombosis. All pa-
tients had popliteo-femoral thrombi that were seen extending
to the common iliac vein in 22 patients and to the inferior vena
cava in the other 6 patients. The patients were initially evalu-
ated with a careful history taking to discover a possible etiol-
ogy. After a thorough examination, complete blood count
and prothrombin time (PT), partial thromboplastin time
(PTT) and INR were determined. The leg circumferences and
D-dimer levels were also measured and recorded before and
after thrombolytic therapy.
2.1. Technique for thrombolysis
With the patient in prone position, the ipsilateral popliteal vein
of the affected limb was visualized by ultrasound. A single wall
puncture was made using a small gauge needle, to avoid inad-
vertent puncture of the adjacent popliteal artery. A hydrophilic
guide wire (Guide Wire M, Terumo Corporation, Tokyo,
Japan) was inserted and advanced through the whole length
of the thrombus. A 5-F vascular sheath was then insertedthrough which all subsequent catheter and wire exchanges
were performed. In addition, the vascular sheath allowed the
intensive care team to obtain blood samples while avoiding
the risk of phlebotomy during thrombolysis. We used the
hydrophilic guide wire before insertion of the vascular sheath
to be sure that we are within the thrombotic vein and to test
the accessibility of the thrombus. After that, contrast material
was injected through the sideway of the vascular sheath to doc-
ument the thrombus, to determine its distal extent, and to visu-
alize collaterals. For infusion of thrombolytic agent, an
infusion wire with multiple side holes and stiffening core (Kat-
zen, Boston Scientiﬁc Corporation, Natick; USA) was used.
The wire was advanced and embedded within the proximal
part of the thrombus. The stiffening core was retracted and
infusion of thrombolytic agent was started as follows: a load-
ing dose of 15 mg Actilyse (rt-PA, Boehringer Mannheim,
Germany) was injected manually as three doses each of them
5 mg at 10 min intervals. Actilyse was then infused into the
thrombus at a rate of 1 mg/h up to 1.5 mg/h with the aid of
an infusion pump over a period of maximum 4 days. Standard
unfractionated heparin (Liquemin, Hoffmann-La Roche,
Grenzach-Wyhlen, Germany) was injected simultaneously in
the side arm of the vascular sheath at a ﬁxed rate of
5000 IU/h and intravenously at a rate of 5000 to 7000 IU/h,
with the dosage adjusted according to the PTT value (2.0 to
3.0 times normal value). Progression of lysis was controlled
by venography every 24 h. Once partial patency is achieved,
the infusion wire was advanced and infusion continued from
the proximal part of residual thrombus. The treatment was
stopped in any case if no residual thrombotic material was vis-
ible or if no further lysis was observed between two consecu-
tive venographies. During thrombolytic therapy, the patient
was rested in bed in intensive care unit since a close observa-
tion is essential to detect any evidence of hemorrhagic compli-
cation. Removal of the vascular sheath was done 12 h after
cessation of the thrombolytic infusion; care was taken with ﬁ-
nal removal for the high risk of local extravasation and
hematoma.
Therapy was continued with the standard anticoagulant,
given in individual doses so that the international normalized
ratio (INR) was greater than 2.5 but less than 4.0. The patients
were followed every week for the ﬁrst 3 months and later every
three months for 1 year.
3. Results
Initial clinical symptoms and the distribution of thrombi are
summarized in Table 1. Treatment outcomes are summarized
in Table 2.
Table 2 Treatment outcomes in 28 patients treated for DVT.
Treatment outcome No. of patients
Lysis of thrombosis
 Complete 23
 Partial 4
 No lysis 1
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the occluded veins occurred in all 28 treated patients. Com-
plete lysis was achieved in 23 patients (82.2%) (Fig. 1 and
2), partial lysis was achieved in 4 (14.3%) (Fig. 3). The last pa-
tient (3.5%) nearly failed after 72 h of thrombolysis mostly due
to old thrombosis (misdiagnosed as muscular skeletal disorder
for more than 2 weeks) (Fig. 4). In this patient only the femo-
ral vein was recanalized after catheter insertion with no lysis of
the thrombus in external iliac, common iliac and inferior vena
cava.
Minor complication of echomosis at the puncture site was
encountered in 10 of 28 (35%). None of these required surgical
intervention or blood transfusion, no major complication
encountered.
Clinical follow-up and Doppler ultrasound evaluation up to
one year of the 23 treated patients who showed complete lysisFigure 1 Complete lysis of popliteo-femoral thrombus in a 51 year old
of the left lower limb. (A&B) venogram obtained before thrombolysis, w
the left popliteal (A), and the superﬁcial femoral vein (B), (arrows). (C)
the thrombus with still occluded distal part of SFV (arrow). (D&E) veno
of the thrombus. Arrow in (E) marks the Katzen infusion guide wire.revealed no rethrombosis or post thrombotic sequelae
syndrome.
4. Discussion
Despite advances in the diagnosis and management of throm-
boembolic disease, it remains a potentially life threatening dis-
order affecting hospitalized patients as well as healthy
individuals [12]. In addition to early risk of pulmonary embo-
lism, late morbidity may develop from recurrent thrombosis
and post thrombotic syndrome [13]. The management of
DVT has evolved in recent years to encompass the outpatient
use of low-molecular weight heparin (LMWH) as well as phar-
macological thrombolysis and mechanical thrombectomy [14].
During the acute phase, proximal DVT is associated with mor-
bidity in the form of leg edema, pain and difﬁcult ambulation
[15]. One of the primary goals of therapy is to relieve outﬂow
obstruction; however this could not be accomplished entirely
by anticoagulation alone because thrombus regression occurs
in only 50% of patients and venous recanalization develops
in only a minority of patients [4,16].
For prevention of pulmonary embolism immediate antico-
agulation with heparin is the standard of care for all patients
with signiﬁcant DVT in the absence of absolute contraindica-
tion. Systemic thrombolysis can be used also to prevent recur-
rent PE when given with or without concomitant heparin [17].female patient, who presented with acute onset of pain and edema
hile patient was in a prone position, shows complete thrombosis of
venogram obtained 24 h after thrombolysis showing partial lysis of
gram obtained 48 h after thrombolysis that showing complete lysis
Figure 2 Complete lysis of the left popliteo-femoral thrombus that extends up to the IVC in a 48 year old female patient. (A&B)
venogram obtained before thrombolysis, while patient was in a prone position, showing complete thrombosis of the left popliteal and
superﬁcial femoral vein (A), and common femoral veins (B), (arrows). (C&D) venogram obtained 24 h after thrombolysis showing
complete lysis of the thrombus up to the external iliac vein, still with partial occlusion of the common iliac vein (short arrows) and the IVC
(long arrow). (E) venogram obtained 48 h after thrombolysis showing complete lysis of the thrombus at the common iliac vein (short
arrow) and the IVC (long arrow).
Figure 3 Partial lysis of the thrombus in a 36 year old male patient. (A) Venogram obtained before thrombolysis, while patient was in a
prone position, shows complete thrombosis of the left popliteal and superﬁcial femoral veins (short arrows). Long arrow demonstrates the
Terumo guide wire advanced through the thrombus. (B) Venogram obtained 24 h after thrombolysis showing partial lysis of the
thrombus. (C&D) Venogram obtained 48 h after thrombolysis shows complete lysis of the thrombus at the popliteal and SFV, with partial
lysis at the common femoral vein (arrows). The occlusion remained after 72 h of thrombolysis with no remarkable change.
60 M. Gomaa et al.As regards the late morbidity of post thrombotic syndrome
which develops in 20% to 50% of patients with DVT, it occurs
more frequently with extensive multi level DVT and when the
oral anticoagulant regimens are inadequate [18,19]. Its symp-
toms include chronic leg heaviness, leg aching and venous clau-
dication, edema, varicosities, hyperpigmentation and non
healing ulcers due to the consequences of the venous valvular
incompetence, venous hypertension and stasis [13]. The above
observations raise the need for treatment therapy that removesthe thrombus to preserve the valvular competence, reduces the
venous outﬂow obstruction and reduces the post thrombotic
syndrome since the anticoagulant therapy prevents thrombus
propagation, PE and recurrent venous thrombosis but it do
not dissolve the occluding thrombus or reduce the venous out-
ﬂow obstruction. These therapies include open surgical throm-
bectomy and pharmacological thrombolytic therapy.
Pharmacological thrombolytic therapy prompts restoration
of venous patency and preservation of venous valve function.
Figure 4 Failed thrombolysis in a 42 year old male patient. (A&B) Venogram obtained before thrombolysis shows complete thrombosis
of the right superﬁcial femoral vein, the iliac veins and the IVC (arrows), with venous return through collaterals. (C&D) Venogram
obtained 72 h after thrombolysis showing complete lysis of the thrombus at the SFV, with partial lysis at the common femoral vein and the
external iliac vein (short arrow). No lysis at the common iliac vein and the IVC (long arrows). (E) CT axial cuts and (F) coronal
reconstruction showing thrombosed both common iliac veins (arrows in E) and IVC (arrow in F).
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DVT. Delivery of the thrombolytic agent directly into the
thrombus offers substantial advantages over systemic adminis-
tration of a thrombolytic agent, which may fail to reach and
penetrate occluded venous segment. Because thrombolytic
agents activate plasminogin in the thrombus, delivery of the
drug to that site enhances its effectiveness. In addition by
focusing the delivery of higher concentration of the drug, lysis
rates can be improved and the duration of treatment can be re-
duced. Subsequently complication associated with exposure of
the patient to systemic thrombolytic therapy might be reduced
[20].
In our study, the initial and long term results appear to be
at least as good as those of other trials involving continuous
infusion catheter directed thrombolytic therapy. In our study
the degree of lysis was found to be a signiﬁcant prediction of
early and continued patency. Complete lysis was achieved in
82% in concordance with the study of Verhaeghe et al. [7]
who were able to restore patency in 79% of thrombosed veins
using rt-PA (alteplase); and with the study done by Chang et
al. [21] who reported that 80% of his patients restored blood
ﬂow after thrombolysis therapy by using alteplase. Our results
were signiﬁcantly better than the result of Mewissen et al. [22]
who achieved complete lysis rate in only 31% using urokinase.
The discrepancy in the results here is mostly due to higher ﬁ-
brin speciﬁcity of rt-PA (like actilyse and alteplase) than those
of urokinase.
In our study no patients would be classiﬁed as having
developed the post thrombotic syndrome, because all patients
are or were asymptomatic for the follow-up period of
12 months. Chang et al. [21] in their study reported similar re-
sult after using alteplase. They found that none of their pa-
tients experienced the post thrombotic syndrome or recurrentthromboembolism. In contrary Prandoni et al. [23] who use
anticoagulant alone (heparin) found that the incidence of post
thrombotic syndrome was 18% at 1 year and almost 25% at
2 years.
In addition our study showed no recurrence in a mean fol-
low-up period of 12 months and no patients were classiﬁed as
having developed rethrombosis. This was in contrast to the
study of Mewissen et al. [22] using Urokinase who found that
almost half of their successfully treated patients had sites of
loss of patency or re-occlusion 6–12 months after treatment.
In another study done by Prandoni et al. [23] they reported a
high percentage of recurrence of about 17% in patients with
DVT treated with anticoagulant alone. Our result was similar
to that of Chang et al. [21] study who reported no recurrent
thrombosis after months of follow up of their patients using
alteplase as thrombolytic agents. In our opinion, this is mostly
due to the use of actilyse which is most speciﬁc and effective
than other thrombolytic agents.
Although there are many effective thrombolytic agents,
actilyse (recombinant human tissue-type plasminogin activa-
tor) is a serine protease that is produced by recombinant
DNA technology and that is chemically identical to human
endogenous rt-PA. It acts by stimulating ﬁbrinolysis of blood
thrombi it promotes the binding of plasminogin to the ﬁbrin
thrombus in conjunction with the increased afﬁnity of ﬁbrin-
bound rt PA for plasminogin and it facilitates the ordered
adsorption of plasminogin and its activator to the ﬁbrin sur-
face [24], it has two characteristics that make it preferable to
intra clot treatment of DVT; its binding afﬁnity for ﬁbrin
and its short half life (approximately 5 min) in the general cir-
culation. Because it binds to the ﬁbrin in a thrombus, actilyse,
unlike streptokinase and urokinase, does not need to be
administered by continuous intra clot infusion. Although ex-
62 M. Gomaa et al.cess actilyse diffuse from the clot into the circulation it is
cleared within 2 h after intra clot installation because of its
short half life.
Catheter directed thrombolysis has two drawbacks: it is la-
bor invasive and there is the bleeding risk [7]. During our study
we encountered only echomosis at the puncture site in 10 of 28
patients. It represents 35 percent which is less than the percent-
age of bleeding found by Verhaegue et al. [7] study who stated
12 patients (50 percent) bleeding at the puncture site with 6
needing blood transfusion. This is mostly due to use of a low
to medium dose of actilyse (1 mg/h up to 1.5 mg/h) in compar-
ison to Verhaege et al. [7] who used a high dose of 3 mg/h, so
low dose and continuous needle access under the ultrasound
guidance are mandatory to avoid the inadvertent puncture of
adjacent vessels such as popliteal artery.
We only used popliteal vein as the venous access site. It al-
lows ante grade catheter traversal of the deep venous valve,
which can be difﬁcult and potentially traumatic to the leaﬂets
when retrograde passage is used.
We did not use IVC ﬁlter since the use of IVC ﬁlter during
thrombolysis has been questioned because of the low incidence
of complication that occurs when lysis is performed without ﬁl-
ter protection [25].
In conclusion, catheter directed thrombolysis using actilyse
appears promising and can be used to dissolve the thrombus
safely and effectively from the deep veins of patients with
symptomatic lower limb DVT. Thrombolytic therapy has the
potential for protecting the patient against chronic venous
insufﬁciency and is related to the achievement and mainte-
nance of patency and the preservation of valve function. The
long term beneﬁts of this form of therapy are promising wher-
ever long term follow-up to 5 year studies are necessary to
evaluate the frequency of chronic venous insufﬁciency.
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